Laurent Garderet, MD, from Hopital Saint-Antoine, Paris, France, discusses the promising role of MRD as a biomarker for guiding the treatment of multiple myeloma (MM) and the questions that must be addressed. He states that although the detection of MRD negativity in MM patients is predictive of their superior overall survival rates and progression-free survival, there are multiple questions relating to the use of MRD that have not yet been answered and thus MRD as a biomarker is not yet ready to be used in daily practice. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.